Oral bisphosphonates in the treatment of osteoporosis: a review

Current Therapeutic Research

Volumn 56, Issue 9, 1995, Pages 831-851

  Francis, Roger M ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; FLUORIDE; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

BONE MASS; BONE STRENGTH; BONE STRUCTURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOMALACIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK;

EID: 0029130033     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0011-393X(95)85087-2     Document Type: Article

References (83)

1. Consensus Development Conference Diagnosis prophylaxis and treatment of osteoporosis
2. Bone densitometry in clinical practice
3. Treatment of bone in elderly subjects: Calcium, vitamin D, fluor, bisphosphonates, calcitonin
4. The use of bisphosphonates in osteoporosis
5. Treatment of postmenopausal osteoporosis with transdermal estrogen
6. Estrogen treatment of patients with established postmenopausal osteoporosis
7. Criteria for successful estrogen therapy in osteoporosis
8. Compliance with hormone therapy
9. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
10. Absorption of oral diphosphonate in normal subjects
11. Clinical pharmacology of alendronate sodium
12. Bisphosphonates: Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease
13. The therapeutic use of bisphosphonates
14. Pamidronate: An unrecognized problem in gastrointestinal tolerability
15. Evaluation of therapeutic efficacy in osteoporosis
16. Prevalence and incidence of vertebral deformities
17. Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites
18. Bone density at various sites for prediction of hip fractures
19. Predisposition to atherosclerosis in the head, heart and legs: The Framingham study
20. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
21. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis
22. Spinal fractures during fluoride therapy for osteoporosis: Relationship to spinal bone density
23. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial
24. Histopathological assessment of endemic skeletal fluorosis
25. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
26. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
27. Four-year study of intermittent-cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
28. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women
29. ADFR (‘coherence’) therapy with phosphorus and etidronate in postmenopausal osteoporotic women
30. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women
31. Coherence therapy does not prevent axial bone loss in osteoporotic women: A preliminary comparative study
32. Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years
33. Comparison of etidronate therapy to calcium and estrogen therapy in postmenopausal women
34. Longterm intermittent cyclical etidronate (ICT) for postmenopausal osteoporosis (PMO)
35. Five years of intermittent cyclical etidronate therapy increases bone mass and reduces vertebral fracture rate in postmenopausal osteoporosis
36. Treatment of postmenopausal osteoporosis with oral alendronate
37. Treatment of postmenopausal osteoporosis with oral alendronate
38. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD
39. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
40. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the menopause
41. Dichloromethylenebisphosfonate in postmenopausal osteoporosis
42. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss
43. Prevention of postmenopausal bone loss by tiludronate
44. Prevention of early postmenopausal bone loss by risedronate: A two-year study
45. Risedronate prevention of bone loss in early postmenopausal women
46. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin
47. Coherence therapy increases vertebral bone mass
48. Etidronate combined with estrogen increases bone mass in osteopenia and osteoporosis
49. The effect of periodic therapy of HEBP (EHDP) on bone mineral density in osteoporosis
50. Concurrent therapy with etidronate and estrogen increases bone mass in osteoporosis and osteopenia
51. The use of etidronate and calcium vs calcium in the treatment of postmenopausal osteopenia First report of interim results
52. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss
53. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis
54. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women
55. Cyclical etidronate therapy prevents bone loss in the early postmenopausal period
56. Success of cyclical etidronate calcium therapy on older osteoporotic subjects
57. A 152 patient double blind placebo controlled study of cyclical etidronate therapy for the prevention of early postmenopausal bone loss
58. Alendronate prevents or reverses bone loss at the spines and hip in recently menopausal women
59. Fracture protection provided by long-term estrogen treatment
60. Menopausal estrogen therapy and hip fractures
61. Hormone replacement therapy and the risk for first hip fracture A prospective population-based cohort study
62. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis
63. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome
64. Data on file, Procter & Gamble Pharmaceutical
65. Results of long-term cyclical etidronate therapy: Bone histomorphometry and clinical correlates
66. Histomorphometric evaluation of bone biopsies after long-term cyclical etidronate treatment
67. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis
68. Bone histomorphometry after long-term treatment with cyclical phosphorus and etidronate
69. Intermittent cyclical etidronate/calcium in postmenopausal osteoporosis
70. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis
71. Histomorphometry from a three-year risedronate bone loss prevention study
72. Merck Sharp & Dohme Limited
73. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
74. Oral alendronate treatment of bone loss in postmenopausal women
75. Rationale for the use of alendronate in osteoporosis
76. Clodronate: An effective agent for the treatment of increased bone resorption
77. Adverse effects of drugs for bone disease
78. Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
79. Tolerability and safety of clodronate therapy in bone diseases
80. Renal failure associated with intravenous diphosphonates
81. Use of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene bisphosphonate for the treatment of hypercalcaemia in patients with renal impairment